Literature DB >> 7932162

Cocaine effects on pulsatile secretion of ACTH in men.

S K Teoh1, Z Sarnyai, J H Mendelson, N K Mello, S A Springer, J W Sholar, M Wapler, J C Kuehnle, H Gelles.   

Abstract

The effects of cocaine on pulsatile secretion of adrenocorticotropic hormone (ACTH) in men were studied under controlled clinical research ward conditions. Eight men with a Diagnostic and Statistical Manual of the American Psychiatric Association Version III, revised, diagnosis of concurrent cocaine and opioid dependence provided their informed consent for participation in this study. After an overnight fast, a challenge dose of cocaine (30 mg i.v.) or placebo was administered under single-blind conditions in a randomized order on 2 study days. Blood samples were collected at 2-min intervals for 76 min during base line and for an additional 76 min after i.v. administration of the challenge dose. Peak plasma cocaine levels of 313.8 +/- 46.5 ng/ml were detected within 2 min after cocaine administration. The cluster analysis program originally described by Veldhuis and Johnson (1986) was used to characterize ACTH pulsatile secretion (Iranmanesh et al., 1990). Acute cocaine administration (30 mg i.v.) significantly increased ACTH mean peak amplitude (P < .05), mean percent increase in peak amplitude, (P < .05), mean peak area (P < .04), total peak area (P < .04) and incremental peak height (P < .04). Mean ACTH valley levels (P < .02) and mean valley nadir (P < .02) were also significantly increased after cocaine administration. We postulate that cocaine stimulates the release of corticotropin releasing factor and that the cocaine-induced secretion of corticotropin releasing factor increases the amplitude of ACTH pulses, because ACTH pulse frequency was not altered by cocaine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932162

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Effects of cocaine on the hypothalamic-pituitary-adrenal axis.

Authors:  L Manetti; F Cavagnini; E Martino; A Ambrogio
Journal:  J Endocrinol Invest       Date:  2014-05-23       Impact factor: 4.256

2.  Effects of chronic cocaine self-administration on norepinephrine transporters in the nonhuman primate brain.

Authors:  Thomas J R Beveridge; Hilary R Smith; Michael A Nader; Linda J Porrino
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

Review 3.  HPA Axis Interactions with Behavioral Systems.

Authors:  Amy E B Packard; Ann E Egan; Yvonne M Ulrich-Lai
Journal:  Compr Physiol       Date:  2016-09-15       Impact factor: 9.090

4.  Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men.

Authors:  Jack H Mendelson; Michelle B Sholar; Nathalie Goletiani; Arthur J Siegel; Nancy K Mello
Journal:  Neuropsychopharmacology       Date:  2005-09       Impact factor: 7.853

5.  Role of the hypothalamic-pituitary-adrenal axis in reinstatement of cocaine-seeking behavior in squirrel monkeys.

Authors:  Buyean Lee; Stefan Tiefenbacher; Donna M Platt; Roger D Spealman
Journal:  Psychopharmacology (Berl)       Date:  2003-03-22       Impact factor: 4.530

6.  Cocaine and cocaethylene: effects on extracellular dopamine in the primate.

Authors:  R N Iyer; J B Nobiletti; P I Jatlow; C W Bradberry
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

7.  Active cocaine use does not increase the likelihood of hyperglycemic crisis.

Authors:  Katherine L Modzelewski; Denis V Rybin; Janice M Weinberg; Sara M Alexanian; Marie E McDonnell; Devin W Steenkamp
Journal:  J Clin Transl Endocrinol       Date:  2017-06-01

8.  Cue-induced cocaine craving enhances psychosocial stress and vice versa in chronic cocaine users.

Authors:  Ann-Kathrin Kexel; Bruno Kluwe-Schiavon; Markus R Baumgartner; Etna J E Engeli; Monika Visentini; Clemens Kirschbaum; Erich Seifritz; Beate Ditzen; Leila M Soravia; Boris B Quednow
Journal:  Transl Psychiatry       Date:  2022-10-11       Impact factor: 7.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.